Who Paid My Doc
Guillermo Davila
Obstetrics & Gynecology Weston, FL Medical Doctor
NPI 1598727034 CMS profile 299727
2950 Cleveland Clinic Blvd, Weston, FL 33331
General payments
$40,401
Research payments
$700
Ownership & investment interest
$11,040
Research they led as principal investigator
$43,335
Through program year 2025, Guillermo Davila of Weston, FL is reported in the CMS Open Payments database as having received $40,401 across 106 general payments and $700 in research payments paid to them. Separately, studies naming them as principal investigator received $43,335 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $11,040 across 2 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $177 | 8 | |
| 2024 | General | $636 | 7 | |
| 2023 | General | $4,056 | 26 | |
| 2023 | Research | $700 | 2 | |
| 2022 | General | $641 | 9 | |
| 2021 | General | $2,194 | 23 | |
| 2020 | General | $7,002 | 6 | |
| 2019 | General | $25,695 | 27 | |
| 2025 | Ownership | $5,520 | 1 | |
| 2024 | Ownership | $5,520 | 1 |
Beside peers
- Guillermo Davila
- Obstetrics & Gynecology median
- Middle half of Obstetrics & Gynecology
- National median
In program year 2025, general payments to Guillermo Davila were reported at $177. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.
Show as a table
| Year | Guillermo Davila | Obstetrics & Gynecology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $25,695 | $172 | $62–$391 | $163 |
| 2020 | $7,002 | $94 | $36–$222 | $114 |
| 2021 | $2,194 | $136 | $42–$369 | $132 |
| 2022 | $641 | $160 | $50–$433 | $149 |
| 2023 | $4,056 | $169 | $56–$423 | $160 |
| 2024 | $636 | $152 | $50–$371 | $164 |
| 2025 | $177 | $158 | $51–$401 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 21 drugsPart D claims
1,798
Drug cost
$125,483
Branded share of claims
19.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 52 | $42,498 | |
| Estradiol | Generic | 636 | $37,907 | |
| Gemtesa Vibegron | Brand | 22 | $16,913 | |
| Trospium Chloride | Generic | 122 | $10,785 | |
| Methenamine Hippurate | Generic | 112 | $9,187 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 170 | $2,151 | |
| Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip | Brand | 88 | $1,714 | |
| Tamsulosin Hcl | Generic | 119 | $1,428 | |
| Clobetasol Propionate | Generic | 15 | $515 | |
| Imipramine Hcl | Generic | 32 | $419 |
The 10 drugs with the highest cost, of 21 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 51 billing codesPaid by Medicare
$261,085
Medicare patients
576
Services billed
3,796
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 70% | |
| Arthritis | 62% | |
| Osteoporosis | 40% | |
| Ischemic heart disease | 35% | |
| Diabetes | 25% | |
| Depression | 25% | |
| Chronic kidney disease | 20% | |
| Cancer | 17% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
108 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Obstetrics & Gynecology in Florida
Steven McCarus
Obstetrics & Gynecology · Celebration, FL
Elliot Cazes
Obstetrics & Gynecology · Tampa, FL
Charles Bloom
Obstetrics & Gynecology · Winter Park, FL
Jay Cohen
Obstetrics & Gynecology · Plantation, FL
Omar Zwain
Obstetrics & Gynecology · Winter Park, FL
Keith Aqua
Obstetrics & Gynecology · Wellington, FL
Related records
Obstetrics & Gynecology in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Obstetrics & Gynecology
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.